Beatriz, living with epilepsy

Belgium,

a growing

biopharma cluster

Didier Malherbe

Managing Director

UCB Belgium

New Delhi, 23 March 2010

Th

e next

generation

bioph

arma

leader

2

Belgium Ranked as best for Innovation, by OECD

“Based on (…) four indicators for

innovation and industrial

development (…) Belgium is by far

the best performing country.”

(OECD)

Th

e next

generation

bioph

arma

leader

3

Tax

Workforce

Infrastructure

Belgian environment for Biopharma Reasons to invest

Knowledge based

economy

Th

e next

generation

bioph

arma

leader

4

Belgium Ranked as best place to do research

In the US magazine, The Scientist, this year, for the first time since the survey's inception in 1993, Belgium was ranked the best country in which to do research.

(The Scientist, November 2007, see table)

The Scientist posted a Web-based questionnaire and invited readers of The Scientist and registrants on The Scientist web site who identified themselves as tenured or tenure-track life scientists working in academia or other non-commercial research organizations to respond. We received 2,072 usable responses.

Th

e next

generation

bioph

arma

leader

5

The largest number of medicines in developmentin the world per capita

Th

e next

generation

bioph

arma

leader

6

Major breakthroughs: HIV/Aids, tuberculosis, malaria, infectiousdiseases, schizophrenia, epilepsy, cancer drugs, immunotherapy, ...

A world center of vaccines research and manufacturing

Track record of Belgian Biopharma

Th

e next

generation

bioph

arma

leader

7

Belgium: unique academic and industrial network

• 16 universities and a high concentration of university hospitals

• A broad offering of science parks with incubation and innovation centers

• Highly specialized research institutes with international reputation

Th

e next

generation

bioph

arma

leader

8

Belgium: A very attractive Tax system for biopharma

75% reduction of payroll taxes for researchers !

Fiscal ruling: The investor describes the facts, allowing the tax administration to determine, in advance, how the tax laws are to be applied on a CASE BY CASE basis. LEGALLY BINDING.

Notional interest: Reduce the tax discrimination between debt-financing and equity-financing. Lower the effective corporate tax rate for all companies

Reduction of sale taxes in proportion of Research investments:Up to 100% reimbursement of your sale taxes paid in Belgium.

Tax on royalty incomes: only 6.8% !

Th

e next

generation

bioph

arma

leader

9

Belgium: The quality of life

A very attractive country to live in.

• The Capital of Europe

• The lowest real estate costs in Europe

• One of the best healthcare systems in the world

• A developed transport network

• A multicultural and multilingual environment

• Brussels, the greenest capital in Europe

• Many high-level international schools

• …..

Th

e next

generation

bioph

arma

leader

10

Positive trend in Wallonia

BioWin, the Health cluster of the Marshall Plan in Wallonia, a plan to stimulate growth, through innovation, where UCB plays an active role

Dynamic DG06 (Economy, Research and Technologies) with several funding models:

• Funding of UCB internal research & investments

• Funding of collaborative research with UCB participation

• Funding of Academic Research through Excellency programs with UCB support as "godfather"

Walloon Government, focusing on key sectors to create new businesses and jobs

Th

e next

generation

bioph

arma

leader

11

WWW.INVESTINBIOPHARMA.BE

Th

e next

generation

bioph

arma

leader

12

UCB Vision

• To become the Patient-Centric global biopharmaceutical leader

• To provide breakthrough innovation for patients suffering from severe diseases

Th

e next

generation

bioph

arma

leader

13

UCB key numbers

9.000 employees (2.000 in Belgium)

Revenues: € 3.1 Billion (2009)

€ 674 Million invested in R&D (2009)

Market capitalisation: € 6 billion (March 8, 2010)

Th

e next

generation

bioph

arma

leader

14

UCB global leadership vs.

Patent exclusivity expirations

# 1 in Allergy

# 1 in Epilepsy

Th

e next

generation

bioph

arma

leader

15

2009 – a turning point Delivering 4 new medicines for patients with severe diseases

Rheumatoid arthritis

Launched in the U.S. (May 2009)Launched in Europe (October 2009)

Epilepsy adjunctive therapy

Launched in the U.S. (June 2009)

Parkinson & Restless legs syndrome

Launched in Europe (June 2009)

Overactive bladder

Launched in the U.S. (April 2009)

Toviaz®

Th

e next

generation

bioph

arma

leader

16

Development pipeline Major projects

1 Complete Response Letter2 Paediatric (2-17 years)

CNS Phase I Phase II Phase III Regulatory status

Keppra® (levetiracetam) Epilepsy – adjunctive therapy (Japan) FiledNovember 2008

Neupro® (rotigotine) Advanced Parkinson's disease (U.S.) CRL1

December 2008

Neupro® (rotigotine) Restless legs syndrome (U.S.) CRL1

December 2008

Xyrem (sodium oxybate) Fibromyalgia

brivaracetam Epilepsy - adjunctive therapy New Phase III trial to start 2010

Vimpat® (lacosamide) Epilepsy – monotherapy (U.S.) Results expected Q2 2013

Vimpat® (lacosamide) Epilepsy – adjunctive therapy2 Results expectedQ4 2010

Vimpat® (lacosamide) Epilepsy – adjunctive therapy PGTC

UCB2892 H3 antagonist CNS

Immunology

Cimzia® (certolizumab pegol) Rheumatoid arthritis (Japan) Results expected Q3 2011

Cimzia® (certolizumab pegol) Ankylosing spondylitis Results expected Q4 2011

Cimzia® (certolizumab pegol) Psoriatic arthritis Results expected Q4 2011

Cimzia® (certolizumab pegol) Juvenile rheumatoid arthritis Phase III trial to start H2 2010

epratuzumab Systemic lupus erythematosus (SLE) Phase III trial to start in H2 2010

CDP7851 (anti-sclerostin) Fracture healing Results expected 2012

CDP7851 (anti-sclerostin) Post-menopausal osteoporosis Results expected 2012

CDP6038 (anti-IL 6) Autoimmune disease

Th

e next

generation

bioph

arma

leader

17

Open innovation at UCB more than 400 partnerships in the world

SclerostinBone loss disorders

oncology

EpratuzumabAutoimmune disease (SLE)

Cyclofluidicdrug discovery

'NeuroAllianz'

consortium Cibles

CNS Research

DianeCNS research

Inflammatory

diseases

Neurocom

Neurodegenerative

diseases

Technology strategy Board

Public support

Federal Ministryof Education

and ResearchPublic support

Regional GrantsPublic support

IMIResearchpartnerships

Th

e next

generation

bioph

arma

leader

18

R&D investors in Belgium The 2008 EU Industrial R&D Investment Scoreboard

781

570

226 200125

96 81 57 450

100

200

300

400

500

600

700

800

UCB

Solvay

Fortis

Agfa

Umicore

Dexia

Barco

Bekae

rt

KBC

http://iri.jrc.ec.europa.eu/research/scoreboard_2008.htm

Th

e next

generation

bioph

arma

leader

19

24.4 24.323.9

21.2

17.8

16.816.4 16.4 16.3

15.1

15

16

17

18

19

20

21

22

23

24

25

UC B (B E) D assault (F R ) Ubiso ft (F R ) Lundbeck(D N )

Ipsen (F R ) Shire (UK) St M icro (F R ) Italte l ( It ) N o vo N o rdisk(D N )

F inmeccanica( IT )

R&D intensity %

An R&D leader in Europe

Top 10 EU companies by R&D intensity, analysis of the 2007 industrial R&D investment scoreboard

European Commission, Sep 2008

Th

e next

generation

bioph

arma

leader

20

New investment: Bio Pilot Plant, Braine

Th

e next

generation

bioph

arma

leader

21

UCB In India: Vision & Mission

VISION

• To heal patients

• To provide excellent professional support to doctors

• To answer needs of our employees and UCB global

• To contribute to the Indian society.

MISSION

1. UCB makes available to Indian patients and doctors highly effective and innovative medicines.

2. UCB partners with Indian companies to optimize processes and operations

3. UCB expands the employees competencies and helps them to realize themselves as well as answers some of India’s needs.

Th

e next

generation

bioph

arma

leader

22

UCB In India

1959: creation of UCB India private limited in JV

1982: Vapi Plant constructed

2001: 100% UCB owned subsidiary

Today: 422 FTEs

Th

e next

generation

bioph

arma

leader

23

Belgium and India Build on each other’s strengths

Belgium India

Academic exchanges

Strengths in Biopharma, ICT, logistic,

environment technologies, …..

Gateway to 500 Mio Europeans

Academic exchanges

Strengths in IT, chemistry,

mathematics, education, …

Gateway to 1.1 Bio Indians